Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126493) titled 'Comparison of Taijilidine and Sufentanil on Propofol Requirements in Hysteroscopic Surgery: A Double-Blind, Dose-Response Study' on June 10.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Foshan Maternity & Child Healthcare Hospital,
Condition:
Gynecological diseases
Intervention:
Group S:Intravenous infusion of 0.10 µg/kg of Sufentanil
Group A:Intravenous infusion of 0.75mg of Taijilidine
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-07-01
Target Sample Size: Group S:30;Group A:30;Group B:30;
Countries of Recruitment:
China
To know more...